Redic, K. A., Hough, S. M., & Price, E. M. (2016). Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: Impact of panobinostat, the first-in-class histone deacetylase inhibitor. Onco Targets Ther.
Citação norma ChicagoRedic, Kimberly A., Shannon M. Hough, and Erika M. Price. "Clinical Developments in the Treatment of Relapsed or Relapsed and Refractory Multiple Myeloma: Impact of Panobinostat, the First-in-class Histone Deacetylase Inhibitor." Onco Targets Ther 2016.
MLA CitationRedic, Kimberly A., Shannon M. Hough, and Erika M. Price. "Clinical Developments in the Treatment of Relapsed or Relapsed and Refractory Multiple Myeloma: Impact of Panobinostat, the First-in-class Histone Deacetylase Inhibitor." Onco Targets Ther 2016.